Citeline-医疗器械行业：2025年第四季度展望报告（英译中）-251031

动脉网2025-11-08

该报告基于一项名为ACCOMPLISH的II期临床试验，该试验招募了57名2至10岁的软骨发育不全患儿。试验结果显示，在最高剂量组（100μg/kg/周）中，接受每周一次皮下注射TransCon CNP治疗52周后，患者的年化身高增长显著优于安慰剂组（5.42厘米 vs 4.35厘米，p=0.0218）。在相同剂量下接受至少六个月治疗的患者也表现出持续且一致的效果。较低剂量组未达到主要终点，但显示...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2582757869?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-08 11:53","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2582757869","market":"us","top_or_hot":-1,"title":"Citeline-医疗器械行业：2025年第四季度展望报告（英译中）-251031","media":"动脉网","content":"<div>\n<p>该报告基于一项名为ACCOMPLISH的II期临床试验，该试验招募了57名2至10岁的软骨发育不全患儿。试验结果显示，在最高剂量组（100μg/kg/周）中，接受每周一次皮下注射TransCon CNP治疗52周后，患者的年化身高增长显著优于安慰剂组（5.42厘米 vs 4.35厘米，p=0.0218）。在相同剂量下接受至少六个月治疗的患者也表现出持续且一致的效果。较低剂量组未达到主要终点，但显示...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110812302894f717bf&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citeline-医疗器械行业：2025年第四季度展望报告（英译中）-251031</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCiteline-医疗器械行业：2025年第四季度展望报告（英译中）-251031\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-08 11:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110812302894f717bf&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>该报告基于一项名为ACCOMPLISH的II期临床试验，该试验招募了57名2至10岁的软骨发育不全患儿。试验结果显示，在最高剂量组（100μg/kg/周）中，接受每周一次皮下注射TransCon CNP治疗52周后，患者的年化身高增长显著优于安慰剂组（5.42厘米 vs 4.35厘米，p=0.0218）。在相同剂量下接受至少六个月治疗的患者也表现出持续且一致的效果。较低剂量组未达到主要终点，但显示...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110812302894f717bf&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4019","symbol_name":"再保险","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110812302894f717bf&s=b","article_id":"2582757869","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110812302894f717bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582757869","pubTimestamp":1762573980,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"试验结果显示，在最高剂量组中，接受每周一次皮下注射TransCon CNP治疗52周后，患者的年化身高增长显著优于安慰剂组。安全性方面，未记录任何与治疗相关的严重不良事件，仅出现轻微注射部位反应。所有完成盲法部分的患者均已进入开放标签扩展期。TransCon CNP已在美国和欧盟获得罕见病药物认定，预计Ascendis公司将在2025年第三季度向欧洲药品管理局提交上市许可申请。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4019":"再保险","KG":"Kestrel"},"translate_title":"Citeline-Medical Device Industry: Outlook Report for the fourth quarter of 2025 (English to Chinese)-251031","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KG":0.9},"content_text":"该报告基于一项名为ACCOMPLISH的II期临床试验，该试验招募了57名2至10岁的软骨发育不全患儿。试验结果显示，在最高剂量组（100μg/kg/周）中，接受每周一次皮下注射TransCon CNP治疗52周后，患者的年化身高增长显著优于安慰剂组（5.42厘米 vs 4.35厘米，p=0.0218）。在相同剂量下接受至少六个月治疗的患者也表现出持续且一致的效果。较低剂量组未达到主要终点，但显示出明显的剂量反应模式。安全性方面，未记录任何与治疗相关的严重不良事件，仅出现轻微注射部位反应。所有完成盲法部分的患者均已进入开放标签扩展期。TransCon CNP已在美国和欧盟获得罕见病药物认定，预计Ascendis公司将在2025年第三季度向欧洲药品管理局提交上市许可申请。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582757869","isCrawlerRequest":true}